Chabiotech

At a glance

Chabiotech filed 80 disclosures in the last 12 months, including 15 5% holder, 5 insider and 4 issuance. The most recent key filing was on Oct 29: A major holder's stake rose from 25.12% to 25.12% (share lending).

Revenue for 2025 was ₩1.27T, up 21.4% on 2024. It made an operating loss of ₩48.8B. Debt was 215% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩646B and operating loss of ₩58.9B.

The 2025 annual report lists 354 employees with an average tenure of 4.9 years and average pay of ₩51.5M, #1387 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩44.6M each on average. It paid no cash dividend for 2025. 차광렬 and related parties held 28.19% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 25.12% on Oct 29.

From the 2025 annual report

Staff: 354 (141 men, 213 women), of whom 20 on fixed-term contracts. Total pay for the year: ₩18.2B. Directors and auditors: 8, paid ₩356.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

차광렬 holds 4.92%; with 22 related parties the group holds 28.19% of common shares at year end (from 29.48% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports